LANTERN PHARMA ($LTRN) posted quarterly earnings results for Q3 2026 on Tuesday, November 17th. The company reported earnings of -$0.81 per share, missing estimates of -$0.36 by $0.45. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $LTRN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LANTERN PHARMA Hedge Fund Activity
We have seen 17 institutional investors add shares of LANTERN PHARMA stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 1,036,000 shares (+inf%) to their portfolio in Q3 2026, for an estimated $1,046,360
- EMPERY ASSET MANAGEMENT, LP removed 299,332 shares (-35.5%) from their portfolio in Q3 2026, for an estimated $302,325
- TWO SIGMA INVESTMENTS, LP added 141,713 shares (+inf%) to their portfolio in Q3 2026, for an estimated $143,130
- UBS GROUP AG added 108,784 shares (+654.1%) to their portfolio in Q3 2026, for an estimated $109,871
- RENAISSANCE TECHNOLOGIES LLC added 77,368 shares (+26.6%) to their portfolio in Q3 2026, for an estimated $78,141
- VOSS CAPITAL, LP removed 50,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $208,500
- CITADEL ADVISORS LLC removed 47,895 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $48,373
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.